Coherus BioSciences Director Departs, Officer Compensation Noted

Ticker: CHRS · Form: 8-K · Filed: Apr 22, 2025 · CIK: 1512762

Sentiment: neutral

Topics: director-departure, officer-compensation, governance

Related Tickers: CHRS

TL;DR

Coherus director Dennis Lanfear is out, and they're talking about exec pay.

AI Summary

Coherus BioSciences, Inc. announced on April 16, 2025, a change in its board of directors. Specifically, Dennis M. Lanfear has departed from his role as a director. The company also reported on compensatory arrangements for its officers.

Why It Matters

Changes in board composition can signal shifts in company strategy or governance, while details on officer compensation are relevant to executive pay and shareholder interests.

Risk Assessment

Risk Level: low — This filing primarily concerns director departure and officer compensation, which are routine corporate governance events and do not inherently indicate significant financial risk.

Key Players & Entities

FAQ

Who is Dennis M. Lanfear and what was his role at Coherus BioSciences, Inc.?

Dennis M. Lanfear was a director of Coherus BioSciences, Inc. and has departed from this role as of April 16, 2025.

What is the primary reason for this 8-K filing?

This 8-K filing is primarily to report the departure of a director and to disclose information regarding compensatory arrangements of certain officers.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on April 16, 2025.

What is the principal executive office address for Coherus BioSciences, Inc.?

The principal executive office address is 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065.

What industry does Coherus BioSciences, Inc. operate in?

Coherus BioSciences, Inc. operates in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) industry, with SIC code 2836.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 22, 2025 by Dennis M. Lanfear regarding Coherus BioSciences, Inc. (CHRS).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing